Amgen Inc.

Type	Public
Traded as	NASDAQ: AMGN NASDAQ-100 Component S&P 500 Component
Industry	Biotechnology
Founded	1980
Headquarters	Thousand Oaks, California, U.S.
Key people	Kevin W. Sharer (Chairman) Robert A. Bradway (President and CEO)
Products	Epogen, Aranesp, Kineret, Enbrel, Neulasta, Neupogen, Nplate, Vectibix, Prolia, Xgeva and Sensipar/Mimpara.
Revenue	US$ 15.053 billion (2010)[1]
Operating income	US$ 5.545 billion (2010)[1]
Net income	US$ 4.627 billion (2010)[1]
Total assets	US$ 43.486 billion (2010)[1]
Total equity	US$ 23.294 billion (2010)[1]
Employees	17,400 (December 2010)[1]
Website	Amgen.com

Amgen (NASDAQ: AMGN, SEHK: 4332) is an American-based multinational biopharmaceutical company headquartered in Thousand Oaks, California. Located in the Conejo Valley, Amgen is the world's largest independent biotechnology firm. Epogen and Neupogen (the company's first products on the market) were the two most successful biopharmaceutical products at the time of their respective releases.

Amgen is the largest employer in Thousand Oaks and second only to the United States Navy in terms of number of people employed in Ventura County. BusinessWeek ranked Amgen first on the S&P 500 for being one of the most "future-oriented" of those five hundred corporations.^[2] BusinessWeek ostensibly calculated the ratio of research and development spending, combined with capital spending, to total outlays; Amgen had the fourth highest ratio, at 506:1000.

The company employs approximately 17,000 staff members. Its products include Epogen, Aranesp, Enbrel, Kineret, Neulasta, Neupogen, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA. Amgen has several collaborative arrangement with Pfizer Inc, GlaxoSmithKline, Takeda Pharmaceutical Company, Kyowa Hakko Kirin, Daiichi Sankyo and Array BioPharma.^[3] It is a leading member of the U.S. Global Leadership Coalition, a coalition of over 400 companies and NGOs that promotes increased funding for US diplomatic and international development programs.^[4] In 2010, Amgen began sponsoring the Tour of California, one of only three major Union Cycliste Internationale events in the United States.

History[link]

Amgen's corporate Gulfstream V departs Fox Field, Lancaster, California

The word AMGen is a portmanteau of the company's original name, Applied Molecular Genetics, which became the official name of the company in 1983 (three years after incorporation and coincident with its initial public offering). The company's first chief executive officer, from 1980, was George B. Rathmann, followed by Gordon M. Binder in 1988, followed by Kevin W. Sharer in 2000. The company has made at least five major corporate acquisitions.

Acquisition history[link]

• 1994 - Synergen, Inc.
• 2000 - Kinetix Pharmaceuticals, Inc.
• 2002 - Immunex Corporation^[5]
• 2004 - Tularik, Inc.
• 2006 - Abgenix, Inc.^[6]
• 2006 - Avidia, Inc.
• 2007 - Ilypsa, Inc.
• 2007 - Alantos Pharmaceuticals Holdings, Inc.
• 2011 - BioVex Group, Inc.
• 2012 - Micromet, Inc.
• 2012 - Mustafa Nevzat İlaç^[7]

Products[link]

As of August 9, 2011, Amgen had twelve approved drugs or therapeutic biologicals for seventeen conditions (conditions lists are highly generalized; see each article for more detail):

• Aranesp (darbepoetin alfa) (for anemia)
• Enbrel (Etanercept) (for various forms of arthritis)
• Epogen (Epoetin) (also known as Procrit; for anemia)
• Kepivance (Palifermin) (for oral mucositis)
• Kineret (Anakinra) (for rheumatoid arthritis)
• Neupogen (Granulocyte-Colony Stimulating Factor) (for neutropenia)
• Neulasta (PEG Granulocyte-Colony Stimulating Factor or "Pegfilgrastim") (for neutropenia)
• Vectibix (Panitumumab) (for colon cancer)
• Sensipar/Mimpara (Cinacalcet) (for Primary & Secondary hyperparathyroidism, a mineral metabolism complication common in patients with kidney failure)
• Nplate (Romiplostim) (for chronic immune thrombocytopenic purpura)
• Prolia (denosumab) (for postmenopausal osteoporosis)
• XGEVA (denosumab) (for the prevention of skeletal-related events (SREs) (pathological fracture, radiation to bone, spinal cord compression or surgery to bone in adults with bone metastases from solid tumors)

Pre Clinical[link]

In other drug discovery phases (Phases I, II, III and in preclinical development), the company has twenty-three pharmacologic agents for twenty-eight conditions; nineteen of the candidates are not currently approved for any indication.

See also[link]

• Kirin-Amgen v Hoechst Marion Roussel, a UK patent case decided by the House of Lords

References[link]

External links[link]

	California portal
	Companies portal

• Official website
• Company Profile at Pharmaceutical Business Review
• Amgen Inc. Company Profile Profile at Google Finance.
• Businessweek.com

v t e Companies of the NASDAQ-100 index Activision Blizzard Adobe Akamai Alexion Pharmaceuticals Altera Amazon.com Amgen Apollo Group Apple Applied Materials Autodesk ADP Avago Baidu Bed Bath & Beyond Biogen Idec BMC Software Broadcom C.H. Robinson CA Technologies Celgene Cerner Check Point Cisco Citrix Cognizant Comcast Costco Ctrip Dell Dentsply DirecTV Dollar Tree eBay Electronic Arts Expedia Expeditors International Express Scripts F5 Networks Fastenal Fiserv Flextronics Fossil Garmin Gilead Sciences Google Green Mountain Coffee Roasters Henry Schein Infosys Intel Intuit Intuitive Surgical KLA Tencor Lam Research Liberty Interactive Life Technologies Linear Technology Marvell Mattel Maxim Integrated Products Microchip Technology Micron Technology Microsoft Monster Beverage Mylan NetApp Netflix News Corporation Nuance Communications Nvidia O'Reilly Auto Parts Oracle Paccar Paychex Perrigo Priceline.com Qualcomm Randgold Resources Research In Motion Ross Stores SanDisk Seagate Sears Sigma-Aldrich Sirius XM Radio Staples Starbucks Stericycle Symantec Teva Pharmaceutical Texas Instruments Verisign Vertex Pharmaceuticals Virgin Media Vodafone Warner Chilcott Whole Foods Market Wynn Resorts Xilinx Yahoo!